These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9255122)

  • 21. A comparative study of subsyde-CR versus meloxicam in rheumatic disorders.
    Patel BR
    J Indian Med Assoc; 2000 May; 98(5):250-2. PubMed ID: 11002624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharma-Clinics. The drug of the month. Meloxicam (Mobic)].
    Scheen AJ
    Rev Med Liege; 1997 Apr; 52(4):309-11. PubMed ID: 9273628
    [No Abstract]   [Full Text] [Related]  

  • 23. Relative value of the NSAIDs, including COX-2 inhibitors and meloxicam.
    Curtiss FR
    J Manag Care Pharm; 2006 Apr; 12(3):265-8. PubMed ID: 16623613
    [No Abstract]   [Full Text] [Related]  

  • 24. [Meloxicam in Russia: 20 years together].
    Karateev AE; Nasonov EN
    Ter Arkh; 2016; 88(12):149-158. PubMed ID: 28635891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of clinical trials and benefit/risk ratio of meloxicam.
    Barner A
    Scand J Rheumatol Suppl; 1996; 102():29-37. PubMed ID: 8628979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic gait analysis assessment of meloxicam efficacy in a sodium urate-induced synovitis model in dogs.
    Cross AR; Budsberg SC; Keefe TJ
    Am J Vet Res; 1997 Jun; 58(6):626-31. PubMed ID: 9185970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meloxicam.
    Fleischmann R; Iqbal I; Slobodin G
    Expert Opin Pharmacother; 2002 Oct; 3(10):1501-12. PubMed ID: 12387696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meloxicam-induced liver toxicity.
    Staerkel P; Horsmans Y
    Acta Gastroenterol Belg; 1999; 62(2):255-6. PubMed ID: 10427794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
    Tavakoli M
    Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effects of treating dairy cows with meloxicam at calving on retained fetal membranes risk.
    Newby NC; Renaud D; Tremblay R; Duffield TF
    Can Vet J; 2014 Dec; 55(12):1196-9. PubMed ID: 25477550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.
    Singh G; Lanes S; Triadafilopoulos G
    Am J Med; 2004 Jul; 117(2):100-6. PubMed ID: 15234645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The selective cox-2 inhibitor meloxicam and salicylate therapy].
    Tóth K
    Ideggyogy Sz; 2005 May; 58(5-6):173-4. PubMed ID: 16021964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meloxicam as a cause of drug-induced autoimmune hepatitis.
    Martínez-Odriozola P; Gutiérrez-Macías A; Ibarmia-Lahuerta J; Muñóz-Sánchez J
    Dig Dis Sci; 2010 Apr; 55(4):1191-2. PubMed ID: 19399620
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Layton D; Heeley E; Hughes K; Shakir SA
    Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and tolerance of stepwise therapy with movalis in rheumatic diseases].
    Tsetkova ES
    Ter Arkh; 2004; 76(12):78-80. PubMed ID: 15724934
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
    Degner F; Lesaffre E; Zeidler H
    Rheumatology (Oxford); 2004 May; 43(5):680-1; author reply 681-2. PubMed ID: 15103042
    [No Abstract]   [Full Text] [Related]  

  • 38. Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder.
    Vidal L; Kneer W; Baturone M; Sigmund R
    Inflamm Res; 2001 Mar; 50 Suppl 1():S24-9. PubMed ID: 11339517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of meloxicam (Metacam) and flunixin (Finadyne) as adjuncts to antibacterial treatment of respiratory disease in fattening cattle.
    Friton GM; Cajal C; Ramirez Romero R; Kleemann R
    Berl Munch Tierarztl Wochenschr; 2004; 117(7-8):304-9. PubMed ID: 15298058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improvement of the efficacy and safety of the treatment of patients with low back pain].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):28-33. PubMed ID: 27845312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.